Skip to content

Author

Kerry L. Reynolds

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Immune Responses in Checkpoint Inhibitor–Associated Cardiovascular Immune–Related Adverse Events

Although immune checkpoint inhibitors have improved cancer outcomes, their use can trigger autoimmune toxicities affecting essentially any organ system. In the cardiovascular system, these immune-related adverse events can manifest as myocarditis, pericarditis, accelerated atherosclerosis, vasculitis, arrhythmias, and...

Kerry L. Reynolds, A.-C. Villani, Z. Drobni et al. · 0 citations
Review Sep 2026

Triplet Immunosuppression for Immune Checkpoint Inhibitor-Related Adverse Events is Associated With High Infection Risk.

BACKGROUND The use of multiagent immunosuppressive therapy (IST) to treat immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) increases the risk of infection. Time-normalized infection rates in a large cohort have not been previously reported. Predictors of opportunistic and nonopportunistic...

Ross D. Merkin, T. Lim, D. Restifo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.